(Reuters) – Sarepta Therapeutics’ gene therapy to treat Duchenne muscular dystrophy failed to reach statistical significance in a late-stage trial, the company reported after the bell on Monday.
(Reporting by Pratik Jain; Editing by Krishna Chandra Eluri)
